<DOC>
	<DOCNO>NCT00169910</DOCNO>
	<brief_summary>This prospective randomized study compare influence area curve ( AUC ) -monitored dual treatment steroid combination either calcineurin inhibitor ( CNI ) mycophenolate mofetil ( MMF ) progression subclinical cardiovascular disease renal transplant recipient . Since CNI detrimental effect cardiovascular risk factor , researcher ' hypothesis renal recipient CNI withdrawal reduction marker cardiovascular disease .</brief_summary>
	<brief_title>VIP : Vascular Imaging Project . Study Progression Cardiovascular Disease Renal Transplant Recipients</brief_title>
	<detailed_description>Stable renal transplant patient maintenance immunosuppressive therapy steroid , calcineurin inhibitor ( CNI ) mycophenolate mofetil ( MMF ) randomize AUC-monitored withdrawal either CNI MMF . The progression cardiovascular marker assess yearly measurement Intima Media Thickness , Pulse Wave Velocity Left Ventricular Hypertrophy group . The duration study 3 year target sample size 100 patient per arm</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Patients , 18 year old , triple maintenance therapy cyclosporine tacrolimus , MMF steroid Informed consent Calculated creatinine clearance &lt; 30 ml/min Multiorgan recipients Patients ( historic ) panel reactive antibody ( PRA ) &gt; 60 % Third renal transplant . Patients receive investigational drug MMF combination cyclosporine tacrolimus Solid malignancy , posttransplant lymphoproliferative disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Renal Transplantation</keyword>
	<keyword>Calcineurin Inhibitor</keyword>
	<keyword>Mycophenolate Mofetil</keyword>
	<keyword>Cardiovascular Disease</keyword>
</DOC>